Of these confirmed CIDP population, 41 patients were excluded, including 30 patients with autoimmune nodopathy (18 with anti-NF155, 8 with anti-NF186, 3 with anti-CNTN1, and 2 with anti-Caspr1), 2 patients with CISP, 3 patients with CCPD and 6 patients with concomitant hematological disorders associated with monoclonal gammopathy. This evidence concerns the gene CNTN1 and monoclonal gammopathy.